Eli Lilly and Company (NYSE:LLY) Shares Sold by Lodestar Private Asset Management LLC

Lodestar Private Asset Management LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 769 shares of the company’s stock after selling 42 shares during the quarter. Lodestar Private Asset Management LLC’s holdings in Eli Lilly and Company were worth $448,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC boosted its holdings in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the last quarter. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $36,000. Finally, Cornerstone Planning Group LLC acquired a new position in Eli Lilly and Company in the 2nd quarter valued at about $33,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 133,785 shares of company stock worth $86,537,034 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $751.64 on Friday. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The firm’s 50 day moving average price is $761.77 and its 200 day moving average price is $652.63. The company has a market cap of $714.18 billion, a P/E ratio of 129.59, a PEG ratio of 1.67 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the business posted $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 12.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LLY shares. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.